Global Neurodegenerative Drugs Market Overview And Scope:
Global Neurodegenerative Drugs Market Size was estimated at USD 122018.71 million in 2022 and is projected to reach USD 172684.57 million by 2028, exhibiting a CAGR of 5.96% during the forecast period.
The Global Neurodegenerative Drugs Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Neurodegenerative Drugs utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, Livzon Pharmaceutical, Haisco Pharmaceutical, Jingxin Pharmaceutical, Dongcheng Biochemicals, Hisun Pharmaceutical, Luye Pharma, Ark Pharmaceutical, Kanghong Pharmaceutical, Huahai Pharmaceutical, BORA PHARMACEUTICALS
Global Neurodegenerative Drugs Market Segmentation
By Type, Neurodegenerative Drugs market has been segmented into:NMDA
SSRIs
Dopamine Inhibitors
By Application, Neurodegenerative Drugs market has been segmented into:
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Neurodegenerative Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Neurodegenerative Drugs market.
Top Key Players Covered in Neurodegenerative Drugs market are:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Objective to buy this Report:
1. Neurodegenerative Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Neurodegenerative Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Neurodegenerative Drugs Market by Type
5.1 Neurodegenerative Drugs Market Overview Snapshot and Growth Engine
5.2 Neurodegenerative Drugs Market Overview
5.3 NMDA
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 NMDA: Geographic Segmentation
5.4 SSRIs
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 SSRIs: Geographic Segmentation
5.5 Dopamine Inhibitors
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Dopamine Inhibitors: Geographic Segmentation
Chapter 6: Neurodegenerative Drugs Market by Application
6.1 Neurodegenerative Drugs Market Overview Snapshot and Growth Engine
6.2 Neurodegenerative Drugs Market Overview
6.3 Parkinson’s Disease
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Parkinson’s Disease: Geographic Segmentation
6.4 Huntington Disease
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Huntington Disease: Geographic Segmentation
6.5 Amyotrophic Lateral Sclerosis
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Amyotrophic Lateral Sclerosis: Geographic Segmentation
6.6 Alzheimer’s Disease
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Alzheimer’s Disease: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Neurodegenerative Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Neurodegenerative Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Neurodegenerative Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 NOVARTIS
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 PFIZER
7.4 MERCK SERONO
7.5 BIOGEN IDEC
7.6 TEVA
7.7 UCB
7.8 BOEHRINGER INGELHEIM
7.9 SANOFI
7.10 GLAXOSMITHKLINE
7.11 LIVZON PHARMACEUTICAL
7.12 HAISCO PHARMACEUTICAL
7.13 JINGXIN PHARMACEUTICAL
7.14 DONGCHENG BIOCHEMICALS
7.15 HISUN PHARMACEUTICAL
7.16 LUYE PHARMA
7.17 ARK PHARMACEUTICAL
7.18 KANGHONG PHARMACEUTICAL
7.19 HUAHAI PHARMACEUTICAL
7.20 BORA PHARMACEUTICALS
Chapter 8: Global Neurodegenerative Drugs Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 NMDA
8.2.2 SSRIs
8.2.3 Dopamine Inhibitors
8.3 Historic and Forecasted Market Size By Application
8.3.1 Parkinson’s Disease
8.3.2 Huntington Disease
8.3.3 Amyotrophic Lateral Sclerosis
8.3.4 Alzheimer’s Disease
Chapter 9: North America Neurodegenerative Drugs Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 NMDA
9.4.2 SSRIs
9.4.3 Dopamine Inhibitors
9.5 Historic and Forecasted Market Size By Application
9.5.1 Parkinson’s Disease
9.5.2 Huntington Disease
9.5.3 Amyotrophic Lateral Sclerosis
9.5.4 Alzheimer’s Disease
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Neurodegenerative Drugs Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 NMDA
10.4.2 SSRIs
10.4.3 Dopamine Inhibitors
10.5 Historic and Forecasted Market Size By Application
10.5.1 Parkinson’s Disease
10.5.2 Huntington Disease
10.5.3 Amyotrophic Lateral Sclerosis
10.5.4 Alzheimer’s Disease
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Neurodegenerative Drugs Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 NMDA
11.4.2 SSRIs
11.4.3 Dopamine Inhibitors
11.5 Historic and Forecasted Market Size By Application
11.5.1 Parkinson’s Disease
11.5.2 Huntington Disease
11.5.3 Amyotrophic Lateral Sclerosis
11.5.4 Alzheimer’s Disease
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Neurodegenerative Drugs Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 NMDA
12.4.2 SSRIs
12.4.3 Dopamine Inhibitors
12.5 Historic and Forecasted Market Size By Application
12.5.1 Parkinson’s Disease
12.5.2 Huntington Disease
12.5.3 Amyotrophic Lateral Sclerosis
12.5.4 Alzheimer’s Disease
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Neurodegenerative Drugs Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 NMDA
13.4.2 SSRIs
13.4.3 Dopamine Inhibitors
13.5 Historic and Forecasted Market Size By Application
13.5.1 Parkinson’s Disease
13.5.2 Huntington Disease
13.5.3 Amyotrophic Lateral Sclerosis
13.5.4 Alzheimer’s Disease
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Neurodegenerative Drugs Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 NMDA
14.4.2 SSRIs
14.4.3 Dopamine Inhibitors
14.5 Historic and Forecasted Market Size By Application
14.5.1 Parkinson’s Disease
14.5.2 Huntington Disease
14.5.3 Amyotrophic Lateral Sclerosis
14.5.4 Alzheimer’s Disease
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Neurodegenerative Drugs Scope:
|
Report Data
|
Neurodegenerative Drugs Market
|
|
Neurodegenerative Drugs Market Size in 2025
|
USD XX million
|
|
Neurodegenerative Drugs CAGR 2025 - 2032
|
XX%
|
|
Neurodegenerative Drugs Base Year
|
2024
|
|
Neurodegenerative Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, Livzon Pharmaceutical, Haisco Pharmaceutical, Jingxin Pharmaceutical, Dongcheng Biochemicals, Hisun Pharmaceutical, Luye Pharma, Ark Pharmaceutical, Kanghong Pharmaceutical, Huahai Pharmaceutical, BORA PHARMACEUTICALS.
|
|
Key Segments
|
By Type
NMDA
SSRIs
Dopamine Inhibitors
By Applications
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
|
